Product catalogue

Excludes Private Label

View all products >

News & Events

At Wockhardt UK we firmly believe that maintaining freedom of choice for diabetic patients is important and we are committed to continue the supply of our Hypurin® Porcine insulins to the UK and Canada for the foreseeable future.

Hypurin® insulins are available in vials and cartridges and are an alternative to human or analogue insulins.

For further information please click the link below.

Our Latest News & Events >

News & Events

Wockhardt announces COVID-19 vaccine partnership with UK Government

3rd August 2020, PRESS RELEASE

Wockhardt announces COVID-19 vaccine partnership with UK Government

Wockhardt, the global pharmaceutical and biotechnology major today announced that it has entered into an agreement with the UK Government to fill finish COVID-19 vaccines. The manufacturing will be undertaken at CP Pharmaceuticals, a subsidiary of Wockhardt based in Wrexham, North Wales. 

As per the terms of the agreement the company has reserved manufacturing capacity to allow for the supply of multiple vaccines to the UK Government in its fight against COVID-19, including AZD1222, the vaccine co-invented by the University of Oxford and its spin-out company, Vaccitech, and licensed by AstraZeneca.

Read more >

Our Products

Wockhardt UK specialises in the manufacture and supply of generic and branded medicines, with a constantly growing portfolio of over 250 product lines.

 

Our products cover many therapy areas including anticoagulation, pain management, anti-infectives, diabetes and antibiotics. They are available in a wide range of preparations, ranging from tablets, capsules and injections, through to liquid medicines, ointments and creams.

Read more >